MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

19.58 -0.07 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 530,494
Open 19.68
Bid (Size) 19.57 (700)
Ask (Size) 19.76 (200)
Prev. Close 19.65
Today's Range 19.49 - 20.04
52wk Range 16.52 - 22.76
Shares Outstanding 65,504,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill

Performance

YTD
-1.5%
-1.5%
1 Month
-5.5%
-5.5%
3 Month
+12.2%
+12.2%
6 Month
+2.7%
+2.7%
1 Year
+13.1%
+13.1%

More News

Read More
News headline image
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
From Innoviva, Inc.
Via Business Wire
News headline image
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗
Via Benzinga
News headline image
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗
Via Chartmill
News headline image
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗
Via Chartmill
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗
Via Chartmill
News headline image
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts ↗
Via Benzinga
News headline image
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗
Via Benzinga
News headline image
Innoviva (INVA) Q2 Sales Jump 64% ↗
Via The Motley Fool
News headline image
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire

Frequently Asked Questions

Is Innoviva, Inc. - Common Stock publicly traded?
Yes, Innoviva, Inc. - Common Stock is publicly traded.
What exchange does Innoviva, Inc. - Common Stock trade on?
Innoviva, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Innoviva, Inc. - Common Stock?
The ticker symbol for Innoviva, Inc. - Common Stock is INVA on the Nasdaq Stock Market
What is the current price of Innoviva, Inc. - Common Stock?
The current price of Innoviva, Inc. - Common Stock is 19.58
When was Innoviva, Inc. - Common Stock last traded?
The last trade of Innoviva, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Innoviva, Inc. - Common Stock?
The market capitalization of Innoviva, Inc. - Common Stock is 1.28B
How many shares of Innoviva, Inc. - Common Stock are outstanding?
Innoviva, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story